|About Us||Patients, Families & Visitors||For Health Professionals||Careers||Research & Training||Ways to Give|
Dr. Joy Mangel
Dr. Mangel is a Consultant in Hematology, Department of Medicine, at the London Health Sciences Centre as well as an Assistant Professor of Medicine at the University of Western Ontario. Currently she is the Program Director, UWO Hematology Residency Program. She also holds a Cross Appointment as an Honourary Consultant in Hematology/Oncology at the LRCP.
Dr. Mangel obtained her medical degree from McGill University. Dr. Mangel did her Internal Medicine and Hematology Training at McGill University. She also held a Clinical Research Fellowship in Toronto at the Sunnybrook Regional Cancer Centre.
Dr. Mangel has a research interest in Hodgkin’s and non-Hodgkin’s Lymphoma, as well as in clinical trials.
Mangel J, Buckstein R, Imrie K, Spaner D, Franssen E, Pavlin P, Boudreau A, Combs D, Berinstein NL. Pharmacokinetic study of patients with follicular or mantle cell lymphoma treated with Rituximab as “in vivo purge” and consolidative immunotherapy following autologous stem cell transplantation. Annals of Oncology 2003;14:758-765
Mangel J, Barth D, MacEachren J, Berinstein NL, Imrie KR. Spontaneous regression of Hodgkin’s disease: two case reports and a review of the literature. Hematology 2003; 8:191-196
Mangel J, Duncan A, Lachance S. Evaluation for the development of 11q23 rearrangements in lymphoma patients treated with a high dose VP-16 and cyclophosphamide salvage regimen. Leukemia and Lymphoma 2003;44:1001-1009
Mangel J, Leitch H.A, Connors J.M, Buckstein R, Imrie K, Spaner D, Crump M, Pennell N, Boudreau A, Berinstein N.L. Intensive chemotherapy and autologous stem cell transplantation plus rituximab is superior to conventional chemotherapy for newly diagnosed advanced stage mantle cell lymphoma: a matched pair analysis. Annals of Oncology 2004;15:283-290
N.L. Berinstein, J. Mangel. Integrating monoclonal antibodies into the management of mantle cell lymphoma. Seminars in Oncology 2004; 31 (suppl 2): 2-6.